References
- Cancer Treat. Rep. v.71 Phase I trial of taxol in patients with advanced malignancies Donehower,R.C.;Rowinsky,E.K.;Grochow,L.B.(et al.)
- J. Clin. Oncol. v.5 Phase I study of taxol using a 50day intermittent schedule Legha,S.S.;Tenney,D.M.;Krakhoff,I.R. https://doi.org/10.1200/JCO.1987.5.8.1232
- Invest. New. Drugs. v.9 A phase Ⅱ study of taxol in patients with malignant melanoma Einzig,A.I.;Hochster,H.;Wiernik,P.H.(et al.)
- Ann. Intern. Med. v.111 Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasm. McGuire,W.P.;Rowinsky,E.K.;Rosenheim,N.B.(et al.) https://doi.org/10.7326/0003-4819-111-4-273
- J. Clin. Oncol. v.10 Phase Ⅱ study and long-term follow up of patients treated with taxol for advanced ovarian adenocarcinoma Einzig,A.I.;Wiernik,P.H.;Sasloff,J.(et al.) https://doi.org/10.1200/JCO.1992.10.11.1748
- Cancer Invest v.9 Phase Ⅱ trial of taxol in patients with metastatic renal cell carcinoma Einzig,A.I.;Gorowski,E.;Sadloff,J.(et al.) https://doi.org/10.3109/07357909109044223
- J. Clin. Oncol. v.10 Phase I study of taxol and granulocyte stimulation factor in patients with refractory ovarian cancer Sarosy,G.;Kohn,E.;Stone,D.A.(et al.) https://doi.org/10.1200/JCO.1992.10.7.1165
- J. Clin. Oncol. v.5 Phase I trial of taxol given as a 24-hour infusion every 21 days: Responses seen in metastatic melanoma Wiernik,P.H.;Schwartz,E.L.;Einzig,A.(et al.) https://doi.org/10.1200/JCO.1987.5.8.1232
- Cancer Treat. Rep. v.71 Phase I study of taxol administered as a short iv infusion daily for 5 days Grem,J.L.;Tutsch,K.D.;Simon,K.L.(et al.)
- J. Clin. Oncol. v.9 Sequences of taxol and cisplatin: A Phase I and pharmacologic study Rowinsky,E.K.;Gilbert,M.R.;McGuire,W.P.(et al.) https://doi.org/10.1200/JCO.1991.9.9.1692
- Adv. Drug Deliv. Rev. v.27 The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Watkins,P.B. https://doi.org/10.1016/S0169-409X(97)00041-0
- J. Pharm. Sci. v.87 Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics Wacher,V.H.;Silverman,J.A.;Zhang,Y.;Benet,L.Z. https://doi.org/10.1021/js980082d
- Pharm. Res. v.16 Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption-theoretical approach Ito,K.;Kusuhara,H.;Sugiyama,Y. https://doi.org/10.1023/A:1018872207437
- Cancer Res. v.54 Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8 Rahman,A.;Korzekwa,K.R.;Grogan,J.;gonzalez,F.J.;Harris,J.W.
- J. Pharmacol. Exp. Ther. v.275 Variability in human cytochrome P450 paclitaxel metabolism Sonnichsen,D.S.;Liu,Q.;Schuetz,E.G.;Schuetz,J.D.;Pappo,A.;Relling,M.V.
- Biochem. Pharmacol. v.46 Short communication; Taxol metabolism in rat hepatocytes Walle,T. https://doi.org/10.1016/0006-2952(93)90336-U
- Clin. Pharmacokinet v.27 Clinical Pharma-cokinetics of paclitaxel Sonnichsen,D.S.;Relling,M.V. https://doi.org/10.2165/00003088-199427040-00002
- Cancer Res. v.54 Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Harris,J.W.;Rahman,A.;Kim,B.R.;Guengerich,F.P.;Collins,J.M.
- Am. J. Cardiol. v.46 Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem Henry,P.D. https://doi.org/10.1016/0002-9149(80)90366-5
- Drugs v.30 Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and relatd cardiovascular disorders Sorkin,E.M.;Clissold,S.P.;Brogden,R.N. https://doi.org/10.2165/00003495-198530030-00002
- J. Med. Chem. v.4 Oxidation of dihydro-pyridine calcium channel blockers and analogues by human liver cytochrome P-450 ⅢA4 Guengerich,F.P.;Brian,W.R.;Iwasaki,M.;Sari,M.A.;Baarnhielm,C.;Berntsson,P.
- Br. J. Pharmacol. v.118 Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial(Caco-2) cells Cavet,M.E.;West,M.;Simmons,N.L. https://doi.org/10.1111/j.1476-5381.1996.tb15550.x
- Cancer Res. v.43 Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers Tsuruo,T.;Iida,M.;Nojiri,H.;Tsukagoshi,S.;Sakurai,Y.
- Br. J. Cancer v.50 Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells Ramu,A.;Spanier,R.;Rahamimoff,H.;Fuks,Z. https://doi.org/10.1038/bjc.1984.207
- Br. J. Cancer v.77 no.7 Phase Ⅱ trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer Lehnert,M.;Mross,K.;Schueller,J.;Thuerlimann,B.;Kroeger,N.;Kupper,H. https://doi.org/10.1038/bjc.1998.192
- Journal of the National Cancer Institute v.84 no.21 Effects of verapamail on the acute toxicity of doxorubicin in vivo Sridhar,R.;Dwivedi,C.;Anderson,J.;Baker,P.B.;Sharma,H.M.;Desai,P.;Engineer,F.N. https://doi.org/10.1093/jnci/84.21.1653
- Biochemical Pharmacology v.38 no.11 Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts Horton,J.K.;Thimmaiah,K.N.;Houghton,J.A.;Horowitz,M.E.;Houghton,P.J. https://doi.org/10.1016/0006-2952(89)90405-X
- J. Chromato. B. v.709 Assay of paclitaxel (Taxol) in plasma and urine by high performance liquid chromatogrphy Manrin,N.;Catalin,J.;Blachon,M.F.;Durand,A. https://doi.org/10.1016/S0378-4347(98)00060-7
- Yakugaku. Zasshi v.114 Determination of new anticancer drug, paclitaxel, in biological fluids by high performance liquid chromatography Mase,H.;Hiraoka,M.;Suzuki,F. https://doi.org/10.1248/yakushi1947.114.5_351
- Computer Program in Biomedicine v.16 LAGRAN program for area and monents in pharmacokinetic analysis Rocci,M.L.;Jusko,W.J. https://doi.org/10.1016/0010-468X(83)90082-X